Sanofi SA has announced its acquisition of Vicebio Ltd, a London-based biotechnology firm, to enhance its respiratory vaccines pipeline. The deal involves an upfront payment of $1.15 billion, with potential milestone payments of up to $450 million. This strategic move introduces Vicebio's 'Molecular Clamp' technology, aimed at improving vaccine design, particularly for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The acquisition aligns with Sanofi's commitment to vaccine innovation, offering a non-mRNA vaccine option and simplifying vaccine storage and distribution. The acquisition is expected to close in the fourth quarter of 2025, pending regulatory approvals.